Anaphore, the San Diego-based developer of novel protein drugs, said today it has named Paul Grayson as its new CEO. Grayson is the former CEO of San Diego-based Fate Therapeutics and was a managing director at Sanderling Ventures. He replaces Kathy Bowdish, who will remain a consultant to Anaphore. Last year, Anaphore formed a partnership with Japan-based Mitsubishi Tanabe that could be worth more than $110 million over time.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
